GSDMDC1 Inhibitors
GSDMDC1, or gasdermin domain-containing protein 1, is a crucial player in cellular processes such as inflammation, apoptosis, and cell proliferation. Its role in these pathways makes it a significant target for research in various diseases, particularly cancer, where dysregulation of GSDMDC1 is often observed. Inflammatory responses, regulated by GSDMDC1, are integral to the body's defense mechanisms against pathogens and tissue damage. However, aberrant activation of GSDMDC1 can lead to excessive inflammation, contributing to the pathogenesis of inflammatory diseases and cancer progression. Additionally, GSDMDC1 is involved in apoptosis, the programmed cell death process essential for maintaining tissue homeostasis. Dysregulated GSDMDC1 activity can disrupt apoptosis, leading to uncontrolled cell growth and tumor development.
The inhibition of GSDMDC1 is a critical area of research aimed at modulating inflammatory responses and regulating cell death pathways. Various mechanisms have been identified for inhibiting GSDMDC1 activity, primarily focusing on targeting signaling pathways involved in its regulation. One common approach is to inhibit upstream kinases or signaling molecules within these pathways, such as the MAPK/ERK, PI3K/AKT, and p38 MAPK pathways. By blocking key components of these pathways, inhibitors effectively suppress GSDMDC1 expression and function, mitigating its pro-inflammatory and pro-tumorigenic effects. These inhibitors disrupt downstream signaling events, impeding the detrimental consequences of GSDMDC1 dysregulation. Overall, elucidating the mechanisms of GSDMDC1 inhibition provides valuable insights into strategies for diseases associated with its aberrant activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits GSDMDC1 through the MAPK/ERK pathway. It targets RAF kinases, which are upstream regulators of ERK, leading to downregulation of GSDMDC1 expression and activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits GSDMDC1 via the EGFR pathway. By blocking EGFR activation, it prevents downstream signaling events that would otherwise upregulate GSDMDC1 expression and function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits GSDMDC1 by targeting the MAPK/ERK pathway. It acts as a selective inhibitor of MEK1 and MEK2, key components of this pathway, thereby suppressing GSDMDC1 activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits GSDMDC1 through the MAPK/ERK pathway. It blocks the activation of MEK1 and MEK2, leading to downstream inhibition of ERK and subsequent downregulation of GSDMDC1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB202190 inhibits GSDMDC1 via the p38 MAPK pathway. By targeting p38 MAPK, it disrupts downstream signaling events involved in GSDMDC1 activation, resulting in its inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits GSDMDC1 through the PI3K/AKT pathway. It blocks PI3K activity, preventing the activation of AKT, which in turn leads to suppression of GSDMDC1 expression and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits GSDMDC1 by targeting the PI3K/AKT pathway. It irreversibly inhibits PI3K activity, resulting in decreased AKT activation and subsequent downregulation of GSDMDC1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits GSDMDC1 via the mTOR pathway. By binding to FKBP12, it inhibits mTOR complex 1 (mTORC1), leading to downstream inhibition of GSDMDC1 and its associated functions. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib inhibits GSDMDC1 through the MAPK/ERK pathway. It selectively inhibits MEK1 and MEK2, upstream kinases of ERK, resulting in suppression of GSDMDC1 expression and activity. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib inhibits GSDMDC1 through the MAPK/ERK pathway. It selectively inhibits MEK1 and MEK2, key regulators of ERK signaling, resulting in downregulation of GSDMDC1 expression and function. | ||||||